AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28706106 — intervention group
Group type: COMPARATOR
Intervention: Control (no IVC filter)
Number of subjects: 240
Study 24906471 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-methyltetrahydrofolate (5-MTHF) 15 mg/day for 3 weeks
Number of subjects: 30
Study 24906471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23913405 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel napadisilate 75 mg once daily
Number of subjects: 162
Study 23913405 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel bisulfate 75 mg once daily
Number of subjects: 162
Study 21871589 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 0.03, 0.1, 0.3, 1.0 or 3.0 mg/kg
Number of subjects: 40
Study 21871589 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 40
Study 21871589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18986507 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional genomic analysis combined with expression or sequence analysis of genes and microRNAs
Number of subjects: 0
Study 18986507 — intervention group
Group type: COMPARATOR
Intervention: Microarray signatures
Number of subjects: 0
Study 16439874 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic immunization with four boosts of ALVAC 1433 and HIV‐LIPO‐6T vaccines followed by three cycles of subcutaneous interleukin‐2
Number of subjects: 70
Study 16439874 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral treatment alone (Control)
Number of subjects: 70
Study 12627987 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a (40kD) 180 microg once a week for 48 weeks (n = 267)
Number of subjects: 531
Study 12627987 — intervention group
Group type: COMPARATOR
Intervention: Unmodified interferon alpha-2a 6 million IU three times a week for 12 weeks followed by 36 weeks of 3 million IU three times a week (n = 264)
Number of subjects: 531
Study 10695888 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen
Number of subjects: 51
Study 9411672 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative treatment with 500 mg of 17‐1A antibody, followed by four 100 mg infusions each month.
Number of subjects: 189
Study 9411672 — intervention group
Group type: COMPARATOR
Intervention: Observation regimen (control group).
Number of subjects: 189
Study 8249618 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine capsules (239 mumol)
Number of subjects: 8
Study 8249618 — intervention group
Group type: COMPARATOR
Intervention: Nimodipine tablets (239 mumol)
Number of subjects: 8
Study 2871538 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol
Number of subjects: 0
Study 2871538 — intervention group
Group type: EXPERIMENTAL
Intervention: Other beta-blockers
Number of subjects: 0
Study 2871538 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline solutions
Number of subjects: 0
Study 31025438 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted protein fortification
Number of subjects: 2
Study 31025438 — intervention group
Group type: COMPARATOR
Intervention: Adjustable protein fortification
Number of subjects: 2
Study 30251187 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral incremental VOR adaptation training lasting 15 min with a 1:1 ratio of head impulses to each side.
Number of subjects: 11
Study 30251187 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol two: VOR adaptation training with a 2:1 ratio of head impulses favoring the adapting side.
Number of subjects: 11
Study 30251187 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol three: All head impulses towards the adapting side, training lasted 7.5 min.
Number of subjects: 11
Study 30251187 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol four: All head impulses towards the adapting side, training lasted 15 min.
Number of subjects: 11
Study 30251187 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol five: All head impulses to the adapting side, exposure time to the visual target during each impulse was doubled.
Number of subjects: 11
Study 26222393 — intervention group
Group type: EXPERIMENTAL
Intervention: PDPH receiving a blood patch
Number of subjects: 10685
Study 26222393 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervix dilatation ≥7 cm
Number of subjects: 10685
Study 26222393 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple punctures
Number of subjects: 10685
Study 26222393 — intervention group
Group type: COMPARATOR
Intervention: Maternal Body Mass Index, age, mode of delivery, performance at night, level of needle insertion
Number of subjects: 10685
Study 26222393 — intervention group
Group type: COMPARATOR
Intervention: Experience of the anesthesiologist
Number of subjects: 10685
Study 25831694 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia (E4) and sevoflurane anesthesia during surgery; continuous epidural analgesia with ropivacaine and fentanyl after surgery
Number of subjects: 350
Study 25831694 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with sevoflurane and fentanyl; systemic administration of opioids after surgery
Number of subjects: 350
Study 22181022 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist behavior similarity to supervisor
Number of subjects: 17
Study 22181022 — intervention group
Group type: EXPERIMENTAL
Intervention: Client behavior similarity to trainee
Number of subjects: 17
Study 19131059 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL‐18 levels in women with PCOS
Number of subjects: 120
Study 19131059 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid IMT in women with PCOS
Number of subjects: 120
Study 19131059 — intervention group
Group type: EXPERIMENTAL
Intervention: Hcy levels in women with PCOS
Number of subjects: 120
Study 19131059 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels in women with PCOS
Number of subjects: 120
Study 19131059 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐6 levels in women with PCOS
Number of subjects: 120
Study 19131059 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA levels in women with PCOS
Number of subjects: 120
Study 19131059 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeostasis model assessment of insulin resistance in women with PCOS
Number of subjects: 120
Study 17828627 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (5 g four times a day for 1 week, followed by the same dosage for the second week)
Number of subjects: 32
Study 17828627 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 g four times a day for 1 week, followed by the same dosage for the second week)
Number of subjects: 32
Study 15668606 — intervention group
Group type: EXPERIMENTAL
Intervention: tibolone 2.5 mg/day
Number of subjects: 43
Study 15668606 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/day + MPA 5 mg/day
Number of subjects: 43
Study 12186625 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg/day
Number of subjects: 1021
Study 12186625 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate 40 mg q.i.d.
Number of subjects: 1021
Study 12186625 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 1021
Study 12186625 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 1021
Study 10024754 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutter airway clearance device
Number of subjects: 15
Study 10024754 — intervention group
Group type: COMPARATOR
Intervention: Chest physiotherapy (CPT)
Number of subjects: 15
Study 10024754 — intervention group
Group type: COMPARATOR
Intervention: Vital Signs, Inc. 9000 PEP therapy
Number of subjects: 15
Study 8834825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 12
Study 8834825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1674677 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (P) 0.08 mg.kg‐1
Number of subjects: 40
Study 1674677 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (V) 0.1 mg.kg‐1
Number of subjects: 40
Study 1674677 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (A) 0.5 mg.kg‐1
Number of subjects: 40
Study 1674677 — intervention group
Group type: EXPERIMENTAL
Intervention: Metocurine 0.1 mg.kg‐1 plus pancuronium 0.02 mg.kg‐1 (M-P)
Number of subjects: 40
Study 1674677 — intervention group
Group type: COMPARATOR
Intervention: Control group (P group)
Number of subjects: 40
Study 7016094 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione-bicarbonate-Ringer's solution (BSS Plus)
Number of subjects: 0
Study 7016094 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 0
Study 31353936 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting training program
Number of subjects: 178
Study 31353936 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 178
Study 31023525 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle-based T2D prevention recommendations including consumption of less than 25 g of sugar daily
Number of subjects: 123
Study 31023525 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of daily sugar intake to less than 25 g
Number of subjects: 123
Study 31023525 — intervention group
Group type: EXPERIMENTAL
Intervention: General lifestyle-based recommendations (including dairy, vegetables, and fruit consumption)
Number of subjects: 123
Study 28340204 — intervention group
Group type: EXPERIMENTAL
Intervention: CO‐CUIDATE program (lumbopelvic stabilization program)
Number of subjects: 46
Study 28340204 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 46
Study 26043591 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine (Lbup)
Number of subjects: 102
Study 26043591 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (Bup)
Number of subjects: 102
Study 26043591 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with epinephrine 1:80,000 (Lid + Epi)
Number of subjects: 102
Study 23579178 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 16
Study 23579178 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M)
Number of subjects: 16
Study 23579178 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (S)
Number of subjects: 16
Study 23579178 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + Sitagliptin (M+S)
Number of subjects: 16
Study 21188440 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and Diclofenac (0.05 mg/kg midazolam and 1.5 mg/kg diclofenac, 15 min before surgical incision)
Number of subjects: 90
Study 21188440 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (1.5 mg/kg diclofenac, 15 min before surgical incision)
Number of subjects: 90
Study 21188440 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and Diclofenac
Number of subjects: 90
Study 21188440 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 90
Study 19395701 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 0
Study 19395701 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided meditation
Number of subjects: 0
Study 19395701 — intervention group
Group type: COMPARATOR
Intervention: Standard care services
Number of subjects: 0
Study 17430327 — intervention group
Group type: EXPERIMENTAL
Intervention: Soda lime
Number of subjects: 15
Study 17430327 — intervention group
Group type: EXPERIMENTAL
Intervention: DrägerSorb Free
Number of subjects: 15
Study 17430327 — intervention group
Group type: EXPERIMENTAL
Intervention: Amsorb Plus
Number of subjects: 15
Study 14991551 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally competent intervention of education and care
Number of subjects: 25
Study 12545682 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheopheresis
Number of subjects: 43
Study 12545682 — intervention group
Group type: COMPARATOR
Intervention: Placebo-Control
Number of subjects: 43
Study 12545682 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheopheresis (subgroup with baseline BCVA worse than 20/40)
Number of subjects: 43
Study 12545682 — intervention group
Group type: COMPARATOR
Intervention: Placebo-Control (subgroup with baseline BCVA worse than 20/40)
Number of subjects: 43
Study 9659700 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg Dinoprostongel (Prepidil)
Number of subjects: 79
Study 9659700 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg Sulprostongel (Nalador)
Number of subjects: 79
Study 9659700 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg Dinoprostongel (repeated applications)
Number of subjects: 79
Study 9659700 — intervention group
Group type: COMPARATOR
Intervention: 1 mg Gemeprost vaginal suppositories (Cergem)
Number of subjects: 79
Study 9659700 — intervention group
Group type: COMPARATOR
Intervention: Repeated therapy with Gemeprost
Number of subjects: 79
Study 7697843 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-micrograms/kg bolus of Integrelin followed by a 1.0-micrograms.kg-1.min-1 infusion for 4 hours
Number of subjects: 150
Study 7697843 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-micrograms/kg bolus of Integrelin followed by a 1.0-micrograms.kg-1.min-1 infusion for 12 hours
Number of subjects: 150
Study 7697843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 2672841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid for 7 days prior to lithotripsy
Number of subjects: 81
Study 2672841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid after lithotripsy
Number of subjects: 81
Study 2672841 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithotripsy
Number of subjects: 81
Study 330481 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam
Number of subjects: 243
Study 330481 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 243
Study 30686501 — intervention group
Group type: EXPERIMENTAL
Intervention: RCS training program
Number of subjects: 64
Study 28394709 — intervention group
Group type: EXPERIMENTAL
Intervention: Fissure sealant (FS) applied to caries-free FPMs, maintained at 6-month intervals.
Number of subjects: 1016
Study 28394709 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (FV) applied at baseline and at 6-month intervals for 3 years.
Number of subjects: 1016
Study 28394709 — intervention group
Group type: EXPERIMENTAL
Intervention: Fissure sealant (FS)
Number of subjects: 1016
Study 28394709 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (FV)
Number of subjects: 1016
Study 25562575 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise trial (90 min of moderate-intensity treadmill running)
Number of subjects: 9
Study 25562575 — intervention group
Group type: COMPARATOR
Intervention: Control trial (no exercise)
Number of subjects: 9
Study 23315286 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 l/min 100% oxygen
Number of subjects: 14
Study 23315286 — intervention group
Group type: COMPARATOR
Intervention: 0.1 l/min air (21% oxygen)
Number of subjects: 14
Study 23315286 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (tubing disconnected from flow-meter)
Number of subjects: 14
Study 20809272 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (22 mg/day as zinc gluconate) for 30 days
Number of subjects: 7
Study 20809272 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin) for 30 days after zinc supplementation
Number of subjects: 7
Study 19243768 — intervention group
Group type: EXPERIMENTAL
Intervention: Gross visual assessment by cytotechnologists
Number of subjects: 51
Study 19243768 — intervention group
Group type: EXPERIMENTAL
Intervention: Gross visual assessment by EUS technologists
Number of subjects: 51
Study 19243768 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine practice of 6 to 7 FNA passes
Number of subjects: 51
Study 19243768 — intervention group
Group type: COMPARATOR
Intervention: Rapid on-site cytopathology
Number of subjects: 51
Study 16757446 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based prevention program for eating disorders with discussion groups
Number of subjects: 72
Study 16757446 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based prevention program for eating disorders without discussion groups
Number of subjects: 72
Study 16757446 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 15326129 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Contour Tonometer (DCT)
Number of subjects: 228
Study 15326129 — intervention group
Group type: COMPARATOR
Intervention: Goldmann Applanation Tonometer (GAT)
Number of subjects: 228
Study 11158071 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily
Number of subjects: 86
Study 11158071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 9243225 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (3.75 mg, 1/2 tablet Dormicum 7.5 mg)
Number of subjects: 46
Study 9243225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 9243225 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (3.75 mg)
Number of subjects: 46
Study 8481669 — intervention group
Group type: EXPERIMENTAL
Intervention: CI(idarubicin)OP
Number of subjects: 44
Study 8481669 — intervention group
Group type: COMPARATOR
Intervention: CH(doxorubicin)OP
Number of subjects: 44
Study 3627392 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 12
Study 3627392 — intervention group
Group type: COMPARATOR
Intervention: Placebo transdermal patches
Number of subjects: 12
Study 31954158 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal 10-μg estradiol tablet
Number of subjects: 289
Study 31954158 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal moisturizer
Number of subjects: 289
Study 31954158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 30033433 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 12521
Study 30033433 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (rosuvastatin + candesartan/hydrochlorothiazide)
Number of subjects: 12521
Study 30033433 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan/hydrochlorothiazide
Number of subjects: 12521
Study 30033433 — intervention group
Group type: COMPARATOR
Intervention: Healthy lifestyles (≥2 factors)
Number of subjects: 12521
Study 27044935 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐RT (70 Gy in 28 fractions over 5.6 weeks)
Number of subjects: 1115
Study 27044935 — intervention group
Group type: COMPARATOR
Intervention: C‐RT (73.8 Gy in 41 fractions over 8.2 weeks)
Number of subjects: 1115
Study 27044935 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐RT
Number of subjects: 1115
Study 25403146 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard monitoring and additional capnography (experimental group)
Number of subjects: 704
Study 25403146 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring (control group)
Number of subjects: 704
Study 25403146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 704
Study 23885609 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at twelve meridians acupoints
Number of subjects: 80
Study 23885609 — intervention group
Group type: COMPARATOR
Intervention: Clonazepam
Number of subjects: 80
Study 19912212 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix subcutaneous 240 mg for 1 month followed by monthly maintenance doses of 80 mg or 160 mg
Number of subjects: 610
Study 19912212 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide 7.5 mg/month
Number of subjects: 610
Study 18564396 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusions stored in plasma
Number of subjects: 117
Study 18564396 — intervention group
Group type: COMPARATOR
Intervention: Platelet transfusions stored in PAS II
Number of subjects: 117
Study 18564396 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusion failure
Number of subjects: 117
Study 18564396 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with one or more 24-hour PLT transfusion failures
Number of subjects: 117
Study 15716891 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid mouthwash (TAMW)
Number of subjects: 16
Study 15716891 — intervention group
Group type: COMPARATOR
Intervention: Factor replacement therapy (FRT)
Number of subjects: 16
Study 12798478 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound umbilical artery flow velocity waveform analysis
Number of subjects: 526
Study 12798478 — intervention group
Group type: COMPARATOR
Intervention: Standard ultrasound biometric assessment
Number of subjects: 526
Study 11106131 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 31
Study 11106131 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP)
Number of subjects: 31
Study 11106131 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 31
Study 9115560 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical history analysis using the top 142 predicting questions
Number of subjects: 288
Study 9115560 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical history analysis using the 30 strongest predictors
Number of subjects: 288
Study 9115560 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal knees)
Number of subjects: 288
Study 1621239 — intervention group
Group type: COMPARATOR
Intervention: MF 701, 100 mg IM b.i.d. (first phase)
Number of subjects: 206
Study 1621239 — intervention group
Group type: COMPARATOR
Intervention: MF 701, 300 mg IM b.i.d. (second phase)
Number of subjects: 206
Study 1621239 — intervention group
Group type: COMPARATOR
Intervention: Placebo (first phase)
Number of subjects: 206
Study 1621239 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MF 701 and placebo)
Number of subjects: 206
Study 6391343 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing masks
Number of subjects: 41
Study 6391343 — intervention group
Group type: COMPARATOR
Intervention: Not wearing masks (Control)
Number of subjects: 41
Study 29460440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive outpatient program plus telephone-based continuing care intervention
Number of subjects: 0
Study 29460440 — intervention group
Group type: COMPARATOR
Intervention: Intensive outpatient program alone
Number of subjects: 0